CMAJ • January 6, 2009; 180 (1).
First published December 10, 2008; doi:10.1503/cmaj.080486
© 2009 Canadian Medical Association or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
Yoon K. Loke, MBBS MD ,
Sonal Singh, MD MPH and
Curt D. Furberg, MD PhD
© 2009 Canadian Medical Association or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
|
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
From the School of Medicine, Health Policy and Practice (Loke), University of East Anglia, Norwich, UK; and the Section on General Internal Medicine, Department of Medicine (Singh), and the Division of Public Health Sciences (Furberg), Wake Forest University School of Medicine, Winston-Salem, USA
Correspondence to: Dr. Yoon K. Loke, School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, UK NR4 7TJ; fax 44 1603 593752 y.loke{at}uea.ac.uk
Background: Rosiglitazone and pioglitazone may increase the incidence of fractures. We aimed to determine systematically the risk of fractures associated with thiazolidinedione therapy and to evaluate the effect of the therapy on bone density.
Methods: We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), other trial registries and product information sheets through June 2008. We selected long-term (
1 year) randomized controlled trials involving patients with type 2 diabetes and controlled observational studies that described the risk of fractures or changes in bone density with thiazolidinediones. We calculated pooled odds ratios (ORs) for fractures and the weighted mean difference in bone density.
Results: We analyzed data from 10 randomized controlled trials involving 13 715 participants and from 2 observational studies involving 31 679 participants. Rosiglitazone and pioglitazone were associated with a significantly increased risk of fractures overall in the 10 randomized controlled trials (OR 1.45, 95% confidence interval [CI] 1.18–1.79; p < 0.001). Five randomized controlled trials showed a significantly increased risk of fractures among women (OR 2.23, 95% CI 1.65–3.01; p < 0.001) but not among men (OR 1.00, 95% CI 0.73–1.39; p = 0.98). The 2 observational studies demonstrated an increased risk of fractures associated with rosiglitazone and pioglitazone. Bone mineral density in women exposed to thiazolidinediones was significantly reduced at the lumbar spine (weighted mean difference –1.11%, 95% CI –2.08% to –0.14%; p = 0.02) and hip (weighted mean difference –1.24%, 95%CI –2.34% to –0.67%; p < 0.001) in 2 randomized controlled trials.
Interpretation: Long-term thiazolidinedione use doubles the risk of fractures among women with type 2 diabetes, without a significant increase in risk of fractures among men with type 2 diabetes.
Related Articles
-
Highlights
Can. Med. Assoc. J. 2009 180: 5.[Full Text] [PDF]
-
Dans ce numéro
Can. Med. Assoc. J. 2009 180: 7.[Full Text] [PDF]
- Thiazolidinediones: Do harms outweigh benefits?
- Lorraine L. Lipscombe, MD MSc
Can. Med. Assoc. J. 2009 180: 16-17.[Full Text] [PDF]
This article has been cited by other articles:
 |
|
 |
|
  D. Mayne, N. R. Stout, and T. J. Aspray Diabetes, falls and fractures Age Ageing, September 1, 2010; 39(5): 522 - 525. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Stramba-Badiale Women and research on cardiovascular diseases in Europe: a report from the European Heart Health Strategy (EuroHeart) project Eur. Heart J., July 2, 2010; 31(14): 1677 - 1681. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Lecka-Czernik PPAR{gamma}, an Essential Regulator of Bone Mass: Metabolic and Molecular Cues IBMS BoneKEy, May 1, 2010; 7(5): 171 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. A. Habib, S. L. Havstad, K. Wells, G. Divine, M. Pladevall, and L. K. Williams Thiazolidinedione Use and the Longitudinal Risk of Fractures in Patients with Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., February 1, 2010; 95(2): 592 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Dormuth, K. Bassett, and B. Carleton Risk of Thiazolidinedione-Associated Fracture Should Be Appropriately Assessed--Reply Arch Intern Med, January 25, 2010; 170(2): 210 - 210. [Full Text] [PDF]
|
|
|
|
 |
|
 L. S. Higgins and A. M DePaoli Selective peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}) modulation as a strategy for safer therapeutic PPAR{gamma} activation Am. J. Clinical Nutrition, January 1, 2010; 91(1): 267S - 272S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. W. Cheatham Peroxisome proliferator-activated receptor translational research and clinical experience Am. J. Clinical Nutrition, January 1, 2010; 91(1): 262S - 266S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L Lipscombe Rosiglitazone was non-inferior to metformin plus sulphonylurea for CV events but increased risk of HF and fractures in type 2 diabetes Evid. Based Med., December 1, 2009; 14(6): 168 - 168. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yamamoto, T. Yamaguchi, M. Yamauchi, and T. Sugimoto Low Serum Level of the Endogenous Secretory Receptor for Advanced Glycation End Products (esRAGE) Is a Risk Factor for Prevalent Vertebral Fractures Independent of Bone Mineral Density in Patients With Type 2 Diabetes Diabetes Care, December 1, 2009; 32(12): 2263 - 2268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Dixit and P. Pandey Beware fractures BMJ, September 29, 2009; 339(sep29_3): b3957 - b3957. [Full Text]
|
|
|
|
|
|
C. R. Dormuth, G. Carney, B. Carleton, K. Bassett, and J. M. Wright Thiazolidinediones and Fractures in Men and Women Arch Intern Med, August 10, 2009; 169(15): 1395 - 1402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Solomon, S. M. Cadarette, N. K. Choudhry, C. Canning, R. Levin, and T. Sturmer A Cohort Study of Thiazolidinediones and Fractures in Older Adults with Diabetes J. Clin. Endocrinol. Metab., August 1, 2009; 94(8): 2792 - 2798. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Reblin Thiazolidinedione use and the risk of fractures Can. Med. Assoc. J., April 14, 2009; 180(8): 841 - 841. [Full Text] [PDF]
|
|
|
|
|
|
Y. K. Loke and S. Singh Two of the authors respond: Can. Med. Assoc. J., April 14, 2009; 180(8): 842 - 843. [Full Text] [PDF]
|
|
|
|
|
|
K. A. Toulis, D. G. Goulis, and A. D. Anastasilakis Thiazolidinedione use and the risk of fractures Can. Med. Assoc. J., April 14, 2009; 180(8): 841 - 842. [Full Text] [PDF]
|
|
|
|
 |
|
 Rosiglitazone, Pioglitazone, and Fractures: A Meta-Analysis Journal Watch (General), January 27, 2009; 2009(127): 6 - 6. [Full Text]
|
|
|
|
|
|
L. L. Lipscombe MD MSc Thiazolidinediones: Do harms outweigh benefits? Can. Med. Assoc. J., January 6, 2009; 180(1): 16 - 17. [Full Text] [PDF]
|
|
eLetters:
Read all eLetters
- Long-term use of thiazolidinediones and fractures in type 2 diabetes: a reappraisal of evidence
- Konstantinos A. Toulis
- CMAJ, 22 Dec 2008 [Full text]